TGF-β/Smad signaling during hepatic fibro-carcinogenesis (Review)
- Authors:
- Katsunori Yoshida
- Miki Murata
- Takashi Yamaguchi
- Koichi Matsuzaki
-
Affiliations: Department of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Osaka 573-1010, Japan - Published online on: July 22, 2014 https://doi.org/10.3892/ijo.2014.2552
- Pages: 1363-1371
-
Copyright: © Yoshida et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
 |
 |
 |
|
Dooley S and Ten Dijke P: TGF-beta in progression of liver disease. Cell Tissue Res. 347:245–256. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pinzani M and Macias-Barragan J: Update on the pathophysiology of liver fibrosis. Expert Rev Gastroenterol Hepatol. 4:459–472. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Date M, Matsuzaki K, Matsushita M, et al: Differential expression of transforming growth factor-beta and its receptors in hepatocytes and nonparenchymal cells of rat liver after CCl4 administration. J Hepatol. 28:572–581. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Date M, Matsuzaki K, Matsushita M, Tahashi Y, Furukawa F and Inoue K: Modulation of transforming growth factor beta function in hepatocytes and hepatic stellate cells in rat liver injury. Gut. 46:719–724. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kisseleva T and Brenner DA: Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 233:109–122. 2008. View Article : Google Scholar | |
|
Moses HL and Serra R: Regulation of differentiation by TGF-beta. Curr Opin Genet Dev. 6:581–586. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts AB and Sporn MB: The transforming growth factor-βs. Peptide Growth Factors and Their Receptors I Berlin: Springer; pp. 419–472. 1990 | |
|
Bellam N and Pasche B: Tgf-beta signaling alterations and colon cancer. Cancer Treat Res. 155:85–103. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuzaki K: Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis. 32:1578–1588. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuzaki K: Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res. 347:225–243. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Derynck R and Miyazono K: The TGF-β Signaling. Cold Spring Harbor Laboratory Press; NY: 2008 | |
|
Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kretzschmar M, Doody J, Timokhina I and Massague J: A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 13:804–816. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuura I, Denissova NG, Wang G, He D, Long J and Liu F: Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 430:226–231. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuzaki K, Kitano C, Murata M, et al: Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. Cancer Res. 69:5321–5330. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kamaraju AK and Roberts AB: Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J Biol Chem. 280:1024–1036. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wicks SJ, Lui S, Abdel-Wahab N, Mason RM and Chantry A: Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol Cell Biol. 20:8103–8111. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Furukawa F, Matsuzaki K, Mori S, et al: p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology. 38:879–889. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mori S, Matsuzaki K, Yoshida K, Furukawa F, et al: TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene. 23:7416–7429. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ho J, Cocolakis E, Dumas VM, Posner BI, Laporte SA and Lebrun JJ: The G protein-coupled receptor kinase-2 is a TGFbeta-inducible antagonist of TGFbeta signal transduction. EMBO J. 24:3247–3258. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Millet C, Yamashita M, Heller M, Yu LR, Veenstra TD and Zhang YE: A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J Biol Chem. 284:19808–19816. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Alarcon C, Zaromytidou AI, Xi Q, et al: Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell. 139:757–769. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuzaki K: Smad phospho-isoforms direct context-dependent TGF-beta signaling. Cytokine Growth Factor Rev. 24:385–399. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yamagata H, Matsuzaki K, Mori S, et al: Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res. 65:157–165. 2005.PubMed/NCBI | |
|
Sekimoto G, Matsuzaki K, Yoshida K, et al: Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res. 67:5090–5096. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida K, Matsuzaki K, Mori S, et al: Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol. 166:1029–1039. 2005. View Article : Google Scholar | |
|
Matsuzaki K, Murata M, Yoshida K, et al: Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 46:48–57. 2007. View Article : Google Scholar | |
|
Murata M, Matsuzaki K, Yoshida K, et al: Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology. 49:1203–1217. 2009. View Article : Google Scholar | |
|
Nagata H, Hatano E, Tada M, et al: Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology. 49:1944–1953. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kawamata S, Matsuzaki K, Murata M, et al: Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis. 17:683–695. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi T, Matsuzaki K, Inokuchi R, et al: Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. Hepatol Res. 43:1327–1342. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Deng YR, Yoshida K, Jin Q, et al: Reversible phospho-Smad3 signaling between tumor-suppression and fibro-carcinogenesis in chronic hepatitis B infection. Clin Exp Immunol. 176:102–111. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Heldin CH, Miyazono K and ten Dijke P: TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature. 390:465–471. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Feng XH and Derynck R: Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 21:659–693. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Miyazono K: Positive and negative regulation of TGF-beta signaling. J Cell Sci. 113:1101–1109. 2000.PubMed/NCBI | |
|
Nakao A, Afrakhte M, Moren A, et al: Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature. 389:631–635. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi H, Abdollah S, Qiu Y, et al: The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell. 89:1165–1173. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Massague J: TGFbeta in cancer. Cell. 134:215–230. 2008. View Article : Google Scholar | |
|
Lin X, Duan X, Liang YY, et al: PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 125:915–928. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hill CS: Nucleocytoplasmic shuttling of Smad proteins. Cell Res. 19:36–46. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Piek EJW, Heyer J, Escalante-Alcalde D, et al: Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem. 276:19945–19953. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YFX, We R and Derynck R: Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature. 383:168–172. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Liu XSY, Constantinescu SN, Karam E, Weinberg RA and Lodish HF: Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA. 94:10669–10674. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Velden JL AJ, Guala AS, Badura EC and Janssen-Heininger YM: c-Jun N-terminal kinase 1 promotes transforming growth factor-β1-induced epithelial-to-mesenchymal transition via control of linker phosphorylation and transcriptional activity of Smad3. Am J Respir Cell Mol Biol. 44:571–581. 2011. | |
|
Hirashima YKH, Suzuki M, Tanaka Y, Kanayama N and Terao T: Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J Biol Chem. 278:26793–26802. 2003. View Article : Google Scholar | |
|
Hu PF, Chen H, Zhong W, Lin Y, Zhang X, Chen YX and Xie WF: Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatol. 51:102–113. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F: Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev. 17:9–17. 2006. View Article : Google Scholar | |
|
Wang G, Matsuura I, He D and Liu F: Transforming growth factor-{beta}-inducible phosphorylation of Smad3. J Biol Chem. 284:9663–9673. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashida T, Decaestecker M and Schnaper HW: Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 17:1576–1578. 2003.PubMed/NCBI | |
|
Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Landstrom M: The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol. 42:585–589. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sorrentino A, Thakur N, Grimsby S, et al: The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 10:1199–1207. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita M, Fatyol K, Jin C, Wang X, Liu Z and Zhang YE: TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell. 31:918–924. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Seki E, Brenner DA and Karin M: A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 143:307–320. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kodama Y, Kisseleva T, Iwaisako K, et al: c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology. 137:1467–1477.e5. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hui L, Zatloukal K, Scheuch H, Stepniak E and Wagner EF: Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest. 118:3943–3953. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Michalopoulos GK and DeFrances MC: Liver regeneration. Science. 276:60–66. 1997. View Article : Google Scholar | |
|
Dooley JS, Lok ASF, Burroughs AK and Heathcote EJ: Sherlock’s Disease of the Liver and Biliary System. 12th edition. Wiley-Blackwell; 2011 | |
|
Tahashi Y, Matsuzaki K, Date M, et al: Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology. 35:49–61. 2002. View Article : Google Scholar | |
|
Yoshida K and Matsuzaki K: Differential regulation of TGF-beta/Smad signaling in hepatic stellate cells between acute and chronic liver injuries. Front Physiol. 3:532012. View Article : Google Scholar : PubMed/NCBI | |
|
Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology. 134:1655–1669. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Friedman SL: Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 1:98–105. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Friedman SL: Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 7:425–436. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rockey DC, Housset CN and Friedman SL: Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest. 92:1795–1804. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Brenner DA, Waterboer T, Choi SK, et al: New aspects of hepatic fibrosis. J Hepatol. 32:32–38. 2000. View Article : Google Scholar | |
|
Marra F: Chemokines in liver inflammation and fibrosis. Front Biosci. 7:d1899–d1914. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Reimann T, Hempel U, Krautwald S, Axmann A, Scheibe R, Seidel D and Wenzel KW: Transforming growth factor-beta1 induces activation of Ras, Raf-1, MEK and MAPK in rat hepatic stellate cells. FEBS Lett. 403:57–60. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Pinzani M, Gesualdo L, Sabbah GM and Abboud HE: Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest. 84:1786–1793. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C and Housset C: Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology. 27:472–480. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Marra F, Arrighi MC, Fazi M, et al: Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor’s actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology. 30:951–958. 1999. | |
|
Nouchi T, Tanaka Y, Tsukada T, Sato C and Marumo F: Appearance of alpha-smooth-muscle-actin-positive cells in hepatic fibrosis. Liver. 11:100–105. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Schmitt-Graff A, Kruger S, Bochard F, Gabbiani G and Denk H: Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol. 138:1233–1242. 1991.PubMed/NCBI | |
|
Pinzani M, Milani S, Herbst H, et al: Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol. 148:785–800. 1996.PubMed/NCBI | |
|
Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K and Gressner AM: Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology. 31:1094–1106. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Stopa M, Anhuf D, Terstegen L, Gatsios P, Gressner AM and Dooley S: Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. J Biol Chem. 275:29308–29317. 2000. View Article : Google Scholar | |
|
Dooley S, Hamzavi J, Breitkopf K, et al: Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology. 125:178–191. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Weng HL, Liu Y, Chen JL, et al: The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin- 13 as driving forces in fibrogenesis. Hepatology. 50:230–243. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Parkin DM, Pisani P and Ferlay J: Global cancer statistics. Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar | |
|
Bosch FX, Ribes J and Borras J: Epidemiology of primary liver cancer. Semin Liver Dis. 19:271–285. 1999. View Article : Google Scholar | |
|
Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (Review). Int J Oncol. 42:1133–1138. 2013.PubMed/NCBI | |
|
Jiang Z, Jhunjhunwala S, Liu J, et al: The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res. 22:593–601. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Brechot C, Pourcel C, Louise A, Rain B and Tiollais P: Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature. 286:533–535. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ and Kew MC: Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 305:1067–1073. 1981. View Article : Google Scholar | |
|
Bonilla Guerrero R and Roberts LR: The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol. 42:760–777. 2005.PubMed/NCBI | |
|
Feitelson MA and Lee J: Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 252:157–170. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P and Buendia MA: The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene. 14:395–404. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Feitelson MA: c-myc overexpression in hepatocarcinogenesis. Hum Pathol. 35:1299–1302. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y and Hino O: Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology. 32:958–961. 2000. View Article : Google Scholar | |
|
Erhardt A, Hassan M, Heintges T and Haussinger D: Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology. 292:272–284. 2002. View Article : Google Scholar | |
|
He Y, Nakao H, Tan SL, et al: Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol. 76:9207–9217. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, Schaack J and Simon FR: Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J. 378:919–928. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao LJ, Wang L, Ren H, Cao J, Li L, Ke JS and Qi ZT: Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp Cell Res. 305:23–32. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hassan M, Ghozlan H and Abdel-Kader O: Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology. 333:324–336. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Choi SH and Hwang SB: Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem. 281:7468–7478. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hassan M, Selimovic D, Ghozlan H and Abdel-Kader O: Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology. 49:1469–1482. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Park KJ, Choi SH, Choi DH, Park JM, Yie SW, Lee SY and Hwang SB: Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2. J Biol Chem. 278:30711–30718. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, Chung WJ, et al: Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology. 138:2509–2518. 2518.e12010. View Article : Google Scholar | |
|
Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, et al: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 78:1527–1531. 1997.PubMed/NCBI | |
|
Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, et al: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 4:1065–1067. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, et al: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. 122:352–365. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Dzieran J, Fabian J, Feng T, et al: Comparative analysis of TGF-beta/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines. PLoS One. 8:e722522013. View Article : Google Scholar : PubMed/NCBI | |
|
Dienstag JL, Schiff ER, Wright TL, et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 341:1256–1263. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Marcellin P, Chang TT, Lim SG, et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 348:808–816. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chang TT, Gish RG, de Man R, et al: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 354:1001–1010. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lai CL, Gane E, Liaw YF, et al: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 357:2576–2588. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Khakoo S, Glue P, Grellier L, et al: Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol. 46:563–570. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Shiratori Y, Imazeki F, Moriyama M, et al: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 132:517–524. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan TR, Ghany MG, Kim HY, et al: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 52:833–844. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida H, Shiratori Y, Moriyama M, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 131:174–181. 1999. View Article : Google Scholar | |
|
Suzuki Y, Kumada H, Ikeda K, et al: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol. 30:743–748. 1999.PubMed/NCBI |
